Table 2.
Univariate Cox proportional hazard regression analysis for overall survival and relapse-free survival in overall osteosarcoma patients
| Characteristics | No. | OS | P | RFS | P |
|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | ||||
| Age, yr., ≥ 30 (vs. < 30) | 11/35 | 2.632 (0.972–7.127) | 0.057 | 3.252 (1.283–8.242) | 0.013 |
| Sex, male (vs. female) | 25/35 | 1.875 (0.530–6.635) | 0.329 | 2.363 (0.674–8.282) | 0.179 |
| Tumor size, cm, > 8 (vs. ≤ 8) | 17/35 | 4.371 (1.393–13.717) | 0.011 | 3.159 (1.166–8.557) | 0.024 |
| Stage, I | 11/35 | 1 | 0.008 | 1 | 0.014 |
| II | 19/35 | 8.528 (1.098–66.238) | 0.040 | 10.139 (1.323–77.728) | 0.026 |
| III-IV | 5/35 | 28.907 (3.133–266.703) | 0.003 | 26.685 (2.862–248.802) | 0.004 |
| Distant metastasis, presence (vs. absence) | 5/35 | 5.404 (1.661–17.578) | 0.005 | 4.174 (1.298–13.418) | 0.016 |
| Histological grade, high (vs. low) | 24/35 | 10.347 (1.362–78.639) | 0.024 | 11.623 (1.541–87.689) | 0.017 |
| PARP1, positive (vs. negative) | 26/35 | 7.834 (1.030–59.563) | 0.047 | 8.355 (1.109–62.967) | 0.039 |
| γH2AX, positive (vs. negative) | 20/35 | 9.192 (2.052–41.166) | 0.004 | 6.540 (1.858–23.023) | 0.003 |
| BRCA1, positive (vs. negative) | 17/35 | 2.796 (0.967–8.088) | 0.058 | 3.741 (1.318–10.620) | 0.013 |
| BRCA2, positive (vs. negative) | 16/35 | 5.194 (1.652–16.331) | 0.005 | 3.436 (1.253–9.424) | 0.017 |
| CSddrm, score 3–4 (vs. score 0–2) | 18/35 | 3.681 (1.712–7.913) | < 0.001 | 13.249 (2.900–60.537) | < 0.001 |
OS overall survival, RFS relapse-free survival, HR hazard ratio, 95% CI 95% confidence interval, CSddrm the combined score for the immunohistochemical expression of PARP1, γH2AX, BRCA1, and BRCA2